William Blair Comments on Avantor’s Q1 Earnings (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Investment analysts at William Blair reduced their Q1 2025 earnings estimates for shares of Avantor in a note issued to investors on Monday, February 10th. William Blair analyst M. Larew now expects that the company will post earnings per share of $0.22 for the quarter, down from their previous forecast of $0.24. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. William Blair also issued estimates for Avantor’s Q2 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.30 EPS, FY2025 earnings at $1.07 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.30 EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.35 EPS and FY2026 earnings at $1.23 EPS.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter in the previous year, the firm earned $0.22 EPS.

Other research analysts also recently issued research reports about the stock. Robert W. Baird dropped their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Raymond James reissued an “outperform” rating and set a $24.00 price target (down from $26.00) on shares of Avantor in a research note on Monday. Stifel Nicolaus reduced their price objective on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. UBS Group reiterated a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a research report on Friday, January 17th. Finally, Morgan Stanley reduced their price target on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.15.

Avantor Price Performance

Shares of NYSE:AVTR opened at $18.06 on Wednesday. The firm has a market cap of $12.29 billion, a price-to-earnings ratio of 39.26, a P/E/G ratio of 3.87 and a beta of 1.28. The firm has a fifty day moving average price of $21.63 and a 200 day moving average price of $23.39. Avantor has a fifty-two week low of $18.00 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54.

Hedge Funds Weigh In On Avantor

Institutional investors have recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB lifted its position in shares of Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after buying an additional 625 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after acquiring an additional 830 shares in the last quarter. UMB Bank n.a. acquired a new stake in Avantor in the third quarter valued at approximately $49,000. Global Retirement Partners LLC grew its holdings in Avantor by 76.7% in the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after purchasing an additional 1,067 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.